glp 1 crackdown FDA steps up on compounded GLP-1s Why the FDA is cracking

Yes, there are some differences

The process might sound complicated, but it doesnt have to be

Those who switched to placebo regained approximately 7% of their body weight, whereas those continuing semaglutide treatment lost an additional 3%

Before starting or continuing GLP-1 therapy, discuss with your provider: your weight loss goals, family history of obesity, previous weight cycling patterns, baseline metabolic health, and financial sustainability

Finally, the development of dual GLP-1/GLP-2 receptor agonists, such as dapiglutide, has shown promise in reducing intestinal transit time and increasing villus height in murine models, representing an exciting future strategy (117)